Plain-English translation of NCT05977673 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to treat people newly diagnosed with Hodgkin lymphoma—a type of blood cancer—who are either 65 years or older, or who have other health conditions that make standard chemotherapy too risky. works by helping your immune system recognize and fight cancer cells. The study will give about 28 patients this medication as an injection every three weeks to see if it works well and is safe for this group.
While standard chemotherapy cures about two-thirds of Hodgkin lymphoma patients, older adults and those with other medical conditions often cannot receive full doses because of side effects and organ damage. This trial aims to find a gentler, more effective option for patients who have been left without good treatment choices.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the medication every three weeks for up to 35 doses (roughly 2 years). Throughout the trial, you would have regular clinic visits for blood tests, scans, and check-ins to monitor how well the treatment is working and whether you experience any side effects. The study team will watch closely for how your lymphoma responds and track your overall health.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
Italy